| Literature DB >> 36259036 |
Tatsuhiko Okayasu1, Ryuichi Ohta2, Fumiko Yamane2, Satoshi Abe3, Chiaki Sano4.
Abstract
Mononeuritis multiplex is a rare form of cerebral nerve palsy caused by various factors. Coronavirus disease 2019 (COVID-19) vaccination could be an etiology of mononeuritis multiplex, which can affect various nerves. Post-COVID-19 and vaccination-related neurological impairments involve cranial nerves such as the facial, trigeminal, and vagal nerves. We report our experience with a 34-year-old man who developed hypoglossal nerve palsy following COVID-19 vaccination, complicated by progressive mononeuritis multiplex. Hypoglossal nerve palsy may occur following COVID-19 vaccination. The symptoms vary and may progress without treatment. Physicians should consider the possibility of mononeuritis multiplex after COVID-19 vaccination and provide prompt treatment for acute symptom progression.Entities:
Keywords: covid-19 vaccination; extremity paralysis; general medicine; hypoglossal nerve palsy; immunoglobulin infusion; mononeuritis multiplex; rural hospital; steroid
Year: 2022 PMID: 36259036 PMCID: PMC9569189 DOI: 10.7759/cureus.29212
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Right sublingual neurological paralysis
Initial laboratory data of the patient
eGFR: estimated glomerular filtration rate; CK: creatine kinase; CRP: C-reactive protein
| Marker | Level | Reference |
| White blood cells | 6.8 | 3.5–9.1 × 103/μL |
| Neutrophils | 51 | 44.0–72.0% |
| Lymphocytes | 32.9 | 18.0–59.0% |
| Monocytes | 8 | 0.0–12.0% |
| Eosinophils | 6.9 | 0.0–10.0% |
| Basophils | 1.2 | 0.0–3.0% |
| Red blood cells | 5.34 | 3.76–5.50 × 106/μL |
| Hemoglobin | 16 | 11.3–15.2 g/dL |
| Hematocrit | 47.8 | 33.4–44.9% |
| Mean corpuscular volume | 89.5 | 79.0–100.0 fl |
| Platelets | 24.6 | 13.0–36.9 × 104/μL |
| Total protein | 6.9 | 6.5–8.3 g/dL |
| Albumin | 4.4 | 3.8–5.3 g/dL |
| Total bilirubin | 0.5 | 0.2–1.2 mg/dL |
| Aspartate aminotransferase | 18 | 8–38 IU/L |
| Alanine aminotransferase | 27 | 4–43 IU/L |
| Alkaline phosphatase | 80 | 106–322 U/L |
| γ-Glutamyl transpeptidase | 50 | <48 IU/L |
| Lactate dehydrogenase | 165 | 121–245 U/L |
| Blood urea nitrogen | 13.9 | 8–20 mg/dL |
| Creatinine | 0.66 | 0.40–1.10 mg/dL |
| eGFR | ≥90 | > 60.0 mL/min/1.73 m2 |
| Serum Na | 137 | 135–150 mEq/L |
| Serum K | 3.9 | 3.5–5.3 mEq/L |
| Serum Cl | 101 | 98–110 mEq/L |
| Serum P | 3.1 | 2.7–4.6 mg/dL |
| Serum Mg | 2 | 1.8–2.3 mg/dL |
| CK | 112 | 56–244 U/L |
| CRP | 0.07 | <0.30 mg/dL |
| Artery blood gas analysis | ||
| pH | 7.418 | 7.35–7.45 |
| PCO2 | 42.5 | 35.0–45.0 mmHg |
| PO2 | 89.3 | 75.0–100.0 mmHg |
| HCO3 | 26.9 | 20.0–26.0 mmol/L |
| Lactate | 1.2 | 0.5–1.6 mmol/L |
| Cerebrospinal fluid testing | ||
| Color | clear | |
| Cell count | 1 | 0–5 /μL |
| Protein | 36 | 15–45 mg/dL |
| Glucose | 57 | 48–83 mg/dL |
| Chloride | 126.5 | 113–128 mEq/L |
Figure 2Edematous findings around both kidneys (blue arrows)